El livro fué lanzado durante el XXIV Congreso Panamericano de Oftalmología em Cancún, México.

Coordinado por el Dr. Luis Porfírio Orózco Gomez, el libro Retinopatia del Prematuro, publicado para los miembros de la SP-ROP, contiene mucho material didactico y cientifico para los que trabajan en la lucha contra la ceguera por la ROP.

El libro está disponible completo para download.

Un “Ojo vigilante en ROP”

No existe un mayor riesgo de la seguridad del paciente relacionado con la visión que el examen y el tratamiento de bebes prematuros en riesgo a desarrollar retinopatía de la prematuridad (ROP).

El examen de retinopatía de la prematuridad (ROP) y el seguimiento, es un cuidado multidisciplinario, intrahospitalario, con un lapso pequeño en el que hay que proveer el examen, tratamiento y seguimiento a tiempo oportuno.

Los retos incluyen proporcionar un cuidado oftálmico a los bebes que están frecuentemente muy enfermos, garantizar que se dé al paciente de alta fácilmente o una transferencia de cuidado fácil, y asegurar que los proveedores de cuidado entiendan la importancia de cumplir con las citas de seguimiento.

El hospital St. Luke’s y el programa Ojo vigilante para retinopatía de prematuridad (©2008 Hospital St. Luke’s de Bethlehem, Pennsylvania) ofrece a los hospitales y a los proveedores de cuidado médico una solución para asegurar la detección de ROP y su seguimiento con tiempo.

El trabajo está disponibilizado en

http://www.paho.org/salud-en-las-americas-2017/?post_type=post_t_es&p=307&lang=fr

Termos de Consentimientos para Screening y Tratamientos en ROP sugeridos por miembros de la SP-ROP

2017 Acta Ophthalmologica

Predictive algorithms for early detection of retinopathy of prematurity

Stefano Piermarocchi, Silvia Bini, Ferdinando Martini, Marianna Berton, Anna Lavini, Elena Gusson, Giorgio Marchini, Ezio Maria Padovani, Sara Macor, Silvia Pignatto, Paolo Lanzetta, Luigi Cattarossi, Eugenio Baraldi, Paola Lago

2017 JAMA Ophthalmology

A Tiered Approach to Retinopathy of Prematurity Screening (TARP) Using a Weight Gain Predictive Model and a Telemedicine Model

Jaclyn Gurwin, Lauren A. Tomlinson, Graham E. Quinn, Gui-shuang Ying, Agnieshka Baumritter, Gil Binenbaum, for the Postnatal Growth and ROP (G-ROP) Study Group and the Telemedicine Approaches to Evaluating Acute-Phase ROP (e-ROP) Cooperative Group

2016 Journal of American Academy of Pediatric Ophthalmology and Strabismus

The Colorado-retinopathy of prematurity model (CO-ROP): postnatal weight gain screening algorithm

Jennifer H. Cao, Brandie D. Wagner, Emily A. McCourt, Ashlee Cerda, Stefan Sillau, Alan Palestine, Robert W. Enzenauer, Rebecca B. Mets-Halgrimson, Miguel Paciuc-Beja, Jane Gralla, Rebecca S. Braverman, Anne Lynch

2016 Ophthalmology

Clinical Models and Algorithms for the Prediction of Retinopathy of Prematurity A Report by the American Academy of Ophthalmology

Amy K. Hutchinson, Michele Melia, Michael B. Yang, Deborah K. VanderVeen, Lorri B. Wilson, Scott R. Lambert

2016 Journal of American Academy of Pediatric Opthalmology and Strabismus

Colorado retinopathy of prematurity model: a multi-institutional validation study

Jennifer H. Cao, Brandie D. Wagner, Ashlee Cerda, Emily A. McCourt, Alan Palestine, Robert W. Enzenauer, Rebecca S. Braverman, et al

2016 World Journal of Clinical Pedatrics

Retinopathy of prematurity: Past, present and future

Parag K Shah, Vishma Prabhu, Smita S Karandikar, Ratnesh Ranjan, Venkatapathy Narendran, Narendran Kalpana

2016 British Medical Journal

Cohort study of growth patterns by gestational age in preterm infants developing morbidity

S Klevebro, P Lundgren, U Hammar, L E Smith, M Bottai, M Domellöf, C Löfqvist, B Hallberg, A Hellström

2015 Neonatology

 The Specificity of the WINROP Algorithm Can Be Significantly Increased by Reassessment of the WINROP

Alarm Pia Lundgren, Elisabeth Stoltz Sjöström, Magnus Domellöf, Lois Smith, Carolyn Wu, Deborah VanderVeen, Ann Hellström, Chatarina Löfqvist  

2013 Plos One

WINROP Identifies Severe Retinopathy of Prematurity at

an Early Stage in a Nation-Based Cohort of Extremely

Preterm Infants

Pia Lundgren, Elisabeth Stoltz Sjöström, Magnus Domellöf, Karin Källen, Gerd Holmström, Anna-Lena Hård, Lois E. Smith, Chatarina Löfqvist, Ann Hellström

2013 Clinical Perinatology

Algorithms for the Prediction of Retinopathy of Prematurity based upon Postnatal Weight Gain

Gil Binenbaum

2013 Archivos Sociedad Española de Oftalmología

El algoritmo WINROP y otras novedades en el cribado de la retinopatía del prematuro

The WINROP algorithm and other innovations in the screening for retinopathy of prematurity

I. González Viejo, C. Ferrer Novella, V. Pueyo Royo

2013 British Journal of Ophthalmology

Reduction in screening for retinopathy of prematurity through risk factor adjusted inclusion criteria

A J van Sorge, E Schalij-Delfos, F T Kerkhoff, L J van Rijn, J LA Van Hillegersberg, LA Van Liempt, O G M Peer, H J Simonz, M Termote

2013 Lancet

Retinopathy of prematurity

Ann Hellström, Lois E H Smith, Olaf Dammann

2006 Archives of Ophthalmology

Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity

Chatarina Löfqvist, Eva Andersson, Jan Sigurdsson, Eva Engström, Anna-Lena Härd, Aimon Niklasson, Lois E H Smith, Ann Hesllström

2017 Retina

Outcomes after laser versus combined laser and bevacizumab treatment for type 1 retinopathy of prematurity in zone I

Authors: JE Moon Yoon, Dong Hoon Shin, Sang Jin Kim, Don-Il Ham, Se Woong Kang, Yun Sil Chang, Won Soon Park

2017 Retina

Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: A Longitudinal Fluorescein Angiographic Study

Authors: Birgit Lorenz, Knut Stieger, Melanie Jager, Christine Stieger, Monika Andrassi-Darida; On behalf of the Giessen Cooperative ROP Study Group

2017 Ophthalmic Surgery, Lasers and Imaging Retina

Incomplete Retinal Vascularization After Ranibizumab Treatment of Retinopathy of Prematurity Ophthalmic Surgery, Lasers and Imaging Retina

Shelley Day, Annis M. Rainey, Clio A. Harper III

2017 Journal of Ophthalmology

Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study

Authors: Qinrui Hu, Yujing Bai, Xiaoli Chen, Lvzhen Huang, Yi Chen, Xiaoxin Li

2017 Retina

Progressive retinal detachment in infants with ROP treated with IV Bevacizumab or Ranibizumab

Authors: YONEKAWA, WEI-CHI WU, NITULESCU, PAUL CHAN, THANOS, THOMAS, TODORICH, KIMBERLY A. DRENSER, MICHAEL T. TRESE, ANTONIO CAPONE JR

2017 Journal of Ophthalmology

Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment

Authors: Qiujing Huang, Qi Zhang, Yu Xu, Xunda Ji, Ping Fei, Jie Peng, Yi-an Li, and Peiquan Zhao

2017 Ophthalmology

Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors

Authors: Qiujing Huang, Qi Zhang, Ping Fei, Yu Xu, Jiao Lyu, Xunda Ji, Jie Peng, Yi-an Li, Peiquan Zhao

2017 Arquivos Brasileiros de Oftalmologia

The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity Processo de vascularização após injeções intravítreas de ranibizumab para retinopatia da prematuridade posterior agressiva

Authors: Emine Alyamaç Sukgen, Yusuf Koçluk

2017 BMJ Ophthalmology

Treatment trends for retinopathy of prematurity in the UK: active surveillance study of infants at risk

Authors: Gillian G W Adams,Catey Bunce,Wen Xing, Lucilla Butler, Vernon Long, Aravind Reddy, Annegret H Dahlmann-Noor

2017 IOVS

Recurrence of Retinopathy of Prematurity After Intravitreal Ranibizumab Monotherapy: Timing and Risk Factors

Authors: Jiao Lyu, Qi Zhang, Chun-Li Chen, Yu Xu, Xun-Da Ji, Jia-Kai Li, Qiu-Jing Huang, Pei-Quan Zhao

2017 JAMA Opthalmology

Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study

Authors: David K.Wallace, Raymond T. Kraker, Sharon F. Freedman, Eric R. Crouch, Amy K. Hutchinson, Amit R. Bhatt, David L. Rogers, Michael B. Yang, Kathryn M. Haider, Deborah K. VanderVeen, Michael Siatkowski, Trevanow Dean, Roy W. Beck, Michael X. Repka, Lois E. Smith, William V. Good, Mary Elizabeth Hartnett, Lingkun Kong, Jonathan M. Holmes, for the Pediatric Eye Disease Investigator Group (PEDIG)

2017 Eye and Brain

Review of effects of anti-VEGF treatment on refractive error

Helen Mintz-Hittner, Megan M Geloneck

2017 Ophthalmology

Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings

Domenico Lepore, Graham E. Quinn, Fernando Molle, Lorenzo Orazi, Antonio Baldascino, Marco H. Ji, Maria Sammartino, Fabio Sbaraglia, Daniela Ricci, Eugenio Mercuri

2017 British Journal of Ophthalmology

Ultra-low-dose intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case series

Roxane J Hillier, Alan J Connor, Ayad E Shafiq

2017 Case Reports in Ophthalmology

Usefulness of Intravitreal Bevacizumab for Retinopathy of Prematurity with Severely Dilated Tunica Vasculosa Lentis and Poor Mydriasis

Tomoaki Higashiyama Sanae Muraki Masahito Ohji

2017 Experimental and Therapeutic Medicine

Early clinical characteristics of bacterial endophthalmitis in retinopathy of prematurity after intravitreal bevacizumab injection: A case report

Jianxun Wang, Daoman Xiang

2016 Retinal Physician

AntiVEGF Agents in ROP: Finding balance between efficacy and adverse events

Authors: Vishak J. John, Claudia G. Hooten, Nick Grisson

2016 Journal of Optometry

Intravitreal anti-VEGF therapy as an adjunct to laser photocoagulation for severe aggressive posterior retinopathy of prematurity

Authors: Sengul Ozdek, Metin Unlu, Gokhan Gurelik, Berati Hasanreisoglu

2016 Retinal and Eye Research

The neural retina in retinopathy of prematurity

Authors: Ronald M. Hansen, Anne Moskowitz, James D. Akula, Anne B. Fulton

2016 Journal of Ophthalmology

Combination of Intravitreal Injection of Ranibizumab and Photocoagulation for the Treatment of Aggressive Posterior

Retinopathy of Prematurity with Vitreous Hemorrhage

Authors: Yu Xu, Xiaoli Kang, Qi Zhang, Qiujing Huang, Jiao Lv, and Peiquan Zhao

2016 Journal of American Academy of Pediatric Ophthalmology and Strabismus

Intravitreal injections of bevacizumab: timing, technique, and outcomes

Author: Helen A. Mintz-Hittner

2016 Journal of American Academy of Pediatric Ophthalmology and Strabismus

Postmortem vitreous bevacizumab levels of an infant treated for retinopathy of prematurity

Authors: Stephen Hypes, Orwa Nasser, Nancy Hanna, William Lawhon, Rachida Bouhenni

2016 Journal of American Academy of Ophthalmology and Strabismus

A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity

Authors: Alireza Khodabande, Mohammad Reza Niyousha, Ramak Roohipoor

2016 The Cochrane Library

Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity

Authors: Mari Jeeva Sankar, Jhuma Sankar, Manisha Mehta, Vishnu Bhat, Renuka Srinivasan

2016 Acta Ophthalmologica

Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison

2016 Journal of Pediatric Ophthalmology and Strabismus

Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity

Authors: Paula Larrañaga-Fragoso, Jesús Peralta, Luciano Bravo-Ljubetic, Natalia Pastora, José Abelairas-Gómez

2016 Ophthalmology

Chronic Vascular Arrest as a Predictor of Bevacizumab Treatment Failure in Retinopathy of Prematurity

Brian C. Toy, Ira H. Schachar, Gavin S.W. Tan, Darius M. Moshfeghi

2016 Scientific Reports

Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy

Authors: Joyce J.T. Chan, Carol P. S. Lam, Madeline K. M. Kwok, Raymond L. M. Wong, Gary K.Y. Lee, Winnie W.Y. Lau, Jason C. S.Yam

2016 Ophthalmology

Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy

Authors: Helen A. Mintz-Hittner, Megan M. Geloneck, Alice Z. Chuang

2016 Ophthalmology

Does Bevacizumab Alter Vascularization Potential in Retinopathy of Prematurity?

Authors: Maram Isaac, Kamiar Mirskandari, Nasrin Tehrani

2016 Ophthalmology

Bevacizumab for Retinopathy of Prematurity: Treatment When Pathology Is Embedded in a Normally Developing Vascular System

Author: William V. Good

2016 Medical Sciences Monitor

Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis

Authors: Simona D. Nicoar?, Anne C. ?tef?nu?, Constanta Nascutzy, Gabriela C. Zaharie, Laura E. Toader, Tudor C. Drugan

2016 Acta Ophthalmologica

Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity

Authors: Reza Karkhaneh, Alireza Khodabande, Mohammad Riazi-Eafahani, Ramak Roohipoor, Fariba Ghassemi, Marjan Imani, Afsar Dastjani Farahani, Nazanin Ebrahimi Adib, Hamidreza Torabi

2016 Ophthalmic Surgery, Lasers and Imaging Retina

Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab

Authors: Laura L. Snyder, Jose Maria Garcia-Gonzalez, Michael J. Shapiro, Michael P. Blair

2016 PLOS ONE

Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity and Bevacizumab Treatment

Authors: Reyin Lien, Mu-Hsien Yu, Kuang-Hung Hsu, Pei-Ju Liao, Yen-Po Chen, ChiChun Lai, Wei-Chi Wu

2016 Journal of American Academy of Pediatric Ophthalmology and Strabismus

Anti-VEGF treatment for ROP: which drug and what dose?

David K. Wallace

2016 Journal of American Academy of Pediatric Ophthalmology and Strabismus

Refractive outcomes following the treatment of retinopathy of prematurity in the anti-VEGF era: A literature review

Authors: Kaveh Abri Aghdam, Joobin Khadamy, Khalil Ghasemi Falavarjani, Irena Tsui 

2016 Clinical Ophthalmology

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity

Authors: Chun-Ju Lin, Yi-Yu Tsai

2016 Current Opinion in Ophthalmology

Antivascular endothelial growth factor in the treatment of retinopathy of prematurity

Authors: Jinali R. Patel, Sinthu S. Ranjan, Barry N. Wasserman

2016 Pediatrics

Hypotension Associated With Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity

Authors: Lu-Hsuan Wu, Yea-Huei Kao Yang, Chyi-Her Lin, Yuh-Jyh Lin, Ching-Lan Cheng

2016 Eye and Brain

Review of effects of anti-VEGF treatment on refractive error

Helen Mintz-Hittner, Geloneck MM

2015 Arquivos Brasileiros de Oftalmologia

Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity

Authors: Muhammet Kazim Erol, Deniz Turgut Coban, Esin Sogutlu Sari, Ahmet Burak Bilgin, Berna Dogan, Ozdemir Ozdemir, Zuhal Ozen Tunay

2015 Arquivos Brasileiros de Oftalmologia

Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity.

Authors: Murat Gunay, Gokan Celik, Betul Onal Gunay, Alev Aktas

2015 Journal Of Pediatric Ophthalmology and Strabismus

Intravitreal Anti-VEGF Therapy as a Treatment for Retinopathy of Prematurity: What We Know After 7 Years

Authors: Michael A. Klufas, Paul Chan

2015 Ophthalmology

Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis

Christopher K. Hwang, G. Baker Hubbard, Amy K. Hutchinson, Scott R. Lambert

2015 Graefes Archive for Clinical and Experimental Ophthalmology

Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity: 27 month follow-up results from Turkey

Authors: Huseyin Yetik, Murat Gunay, Sarkis Sirop, Ziya Salihoglu

2015 Archivos de la Sociedad Española de Oftalmología

Uso off-label de bevacizumab intravítreo en retinopatía del prematuro severa

L.E. Alba, R.A. Zaldua, R.A. Masini

2015 Journal of Ophthalmology

Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity

Authors: Simona Delia Nicoara, Constanta Nascutzy, Criustina Cristian, Iulian Irimescu, Anne Claudia Stefanut, Gabriela Zaharie, Tudor Drugan 

2015 Canadian Journal of ophthalmology

Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent

Authors: Kamiar Mireskandari, Megan E. Collins, Nasrin Tehrani

2015 Ophthalmologica

Refractive Error in Patients with Retinopathy of Prematurity after Laser Photocoagulation or Bevacizumab Monotherapy

Authors: Hsi-Kung Kuo, Ting Sun, Mei-Yung Chung, Yi-Hao Chen 

2015 International Ophthalmology Clinics

Laser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity

Authors: Ilya Leskov, Shizuo Mukai

2015 Japanese Journal of Ophthalmology

Buckling surgery and supplemental intravitreal bevacizumab or photocoagulation on stage 4 retinopathy of prematurity eyes

Authors: Yukiko Futamura, Tetsu Asami, Norie Nonobe, Shu Kachi, Yasuki Ito, Yoshiaki Sato, Masahiro Hayakawa, Hiroko Terasaki

2015 Journal of Pediatric Ophthalmology and Strabismus

Ultra-Low Dose of Intravitreal Bevacizumab in the Treatment of Retinopathy of Prematurity

Authors: Alan J. Connor, Vasileios T. Papastavrou, Roxane J. Hillier, Ayad Shafiq

2015 Journal of American Academy of Pediatric Ophthalmology and Strabismus

Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser

Authors: Maram Isaac, Kamiar Mireskandari, Nasrin Tehrani

2015 BMC Ophthalmology

Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease

Authors: Marcel N Menke, Carten Framme, Mathias Nelle, Markus R Berger, Veit Sturm, Sebastian Wolf

2015 Retina

Plasma concentrations of vascular endothelial growth factor (VEGFafter bevacizumab intravitreal injection in infants with retinopathy of prematurity

Authors: Yoo Rha Hong, Young Ho Kim, Soo Young Kim, Gi Yup Nam, Hee Jong Cheon, San Joon Lee

2015 Journal of Pediatrics and Child Health

Retinopathy of prematurity: New developments bring concern and hope

Author: Brian A Darlow

2015 IOVS

Pharmacokinetics of Bevacizumab and Its Effects on Serum VEGF and IGF-1 in Infants With Retinopathy of Prematurity

Authors: Lingkun Kong,Amit R. Bhatt, Ann B. Demny, David K. Coats, Alexa Li, Effie Z. Rahman, O’Brian E. Smith, Paul G. Steinkuller

2015 JAMA Ophthalmology

Serum Levels of Vascular Endothelial Growth Factor and Related Factors After Intravitreous Bevacizumab Injection for Retinopathy of Prematurity

Authors: Wei-Chi Wu, Reyin Lien, Pei-Ju Liao, Nan-Kai Wang, Yen-Po Chen, An-Ning Chao, Kuan-Jen Chen, Tun-Lu Chen, Yih-Shiou Hwang, Chi-Chun Lai

2015 Retina

Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity: Comparison Between Ranibizumab and Bevacizumab

Authors: San-Ni Chen, Iebin Lian, Ya-Chi Hwang, Yi-Hsing Chen, Yao-Chung Chang, Kun-Hsien Lee, Chih-chun Chuang, Wei-Chi Wu

2015 Retina

Efficacy of Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents for Stage 4 Retinopathy of Prematurity

Authors: Hui-Chen Cheng, Shui-Mei Lee, Yi-Ting Hsieh, Po-Kang Lin

2014 Journal of Ophthalmology

Posterior Pole Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab Injection in Posterior Retinopathy of Prematurity

Authors: Rebecca Kim, Yu Cheol Kim

2014 Clinical Perinatology

Vascular Endothelial Growth Factor Antagonist Therapy for Retinopathy of Prematurity

Author: M. Elizabeth Hartnett

2014 Journal of American Academy of Pediatric Ophthalmology and Strabismus

Late recurrence of retinopathy of prematurity after treatment with both intravitreal bevacizumab and laser

Authors: Wendy Chen, Gil Binenbaum, Karen Karp,Agnieshka Baumritter, Denise J. Pearson, Albert M. Maguire, Graham E. Quinn

2014 Ophthalmology

Intravitreal Bevacizumab versus Laser Treatment in Type 1 Retinopathy of Prematurity: Report on Fluorescein Angiographic Findings

Authors: Domenico Lepore, Graham E. Quinn, Fernando Molle, Antonio Baldascino, Lorenzo Orazi, Maria Sammartino, Velia Purcaro, Carmen Giannantonio, Patrizia Papacci, Costantino Romagnoli

2014 Acta Ophthalmologica

Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies

Authors: Sang Woo Park, Hyun Ho Jung, Hwan Heo

2014 Canadian Journal of Ophthalmology

Intravitreal bevacizumab for exudative retinal detachment post laser therapy for retinopathy of prematurity

Authors: David Ehmann, Mark Greve

2014 Acta Ophthalmologica

Intravitreal low-dosage bevacizumab for retinopathy of prematurity

Authors: Bjorn C. Harder, Stefan von Baltz, Jost B. Jonas, Frank C. Schlichtenbrede

2014 Journal of Pediatric Ophthalmology and Strabismus

A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.

Authors: Yaz Y, Erol N, Gursoy H, Basmak H, Bilgec MD

2014 Eye

Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes

Authors: Y-H Chen, S-N- Chen, R-I Lien, C-P Shih

2014 JAMA Ophthalmology

Refractive Outcomes Following Bevacizumab Monotherapy Compared With Conventional Laser Treatment: A Randomized Clinical Trial

Authors: Megan M. Geloneck, Alice Z. Chuang, W. Lloyd Clark, Michael G. Hunt, Alan A. Norman, Eric A. Packwood, Khaled A. Tawansy, Helen A. Mintz-Hittner, for the BEAT-ROP Cooperative Group

2014 Japanese Journal of Ophthalmology

Intravitreal injection of bevacizumab for retinopathy of prematurity

Authors: Kazuki Kuniyoshi, Koji Sugioka, Hiroyuki Sakuramoto, Shunji Kusaka, Norihisa Wada, Yoshikazu Shimomura

2014 Acta Ophthalmologica

Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity

Authors: Sarah Moran, Michael O’Keefe, Claire Hartnett, Bernadette Lanigan, John Murphy, Veronica Donoghue

2014 Retina

Combined Intravitreal Bevacizumab Injection and Zone I Sparing Laser Photocoagulation in Patients with Zone I Retinopathy of Prematurity

Authors: Jaeryung Kim, Sang Jin Kim, Yun Sil Chang, Won Soon Park

2013 Clinical Perinatology

Current and Future Trends in Treatment of Severe Retinopathy of Prematurity

Authors: David K. Wallace, Katherine Y. Wu

2013 Journal of American Academy of Pediatric Ophthalmology and Strabismus

Exudative retinopathy and detachment: A late reactivation of retinopathy of prematurity after intravitreal bevacizumab

Authors: Shaun Ittiara, Michael P. Blair, Michael J. Shapiro, Steven J. Lichtenstein

2013 Journal of Optometry

Intravitreal anti-VEGF therapy as an adjunct to laser photocoagulation for severe aggressive posterior retinopathy of prematurity

Authors: Sengul Ozdek, Metin Unlu, Gokhan Gurelik, Berati Hasanreisoglu

2013 American Journal of Ophthalmology

An Updated Study of the Use of Bevacizumab in the Treatment of Patients with Prethreshold Retinopathy of Prematurity in Taiwan

Authors: Wei-Chi Wu, Hsi-Kung Kuo, Po-Ting Yeh, Chung-May Yang, Chi-Chun Lai, San-Ni Chen

2013 Eye

Prolonged follow-up period following intravitreal bevacizumab injection for stage 3 þ retinopathy of prematurity

Authors: TA de Klerk, DY Park, S Biswas 

2013 Journal of Pediatric Ophthalmology and Strabismus

Dramatic Regression of Persistent Tunica Vasculosa Lentis Associated With Retinopathy of Prematurity Following Treatment With Intravitreal Bevacizumab

Authors: Darin R. Goldman, Caroline R. Baumal

2013 Pediatrics International

Intravitreal bevacizumab monotherapy for retinopathy of prematurity

Alparslan S¸ahin,1 Muhammed Sahin, Abdullah Kürsat Cingü, Yasin Ç?nar, Fatih Mehmet Türkcü, Harun Yüksel, Savas¸ Kaya, Seyhmus Ar?, I?hsan Çaça

2013 JAMA Ophthalmology

Recurrence of Retinopathy of Prematurity Following Bevacizumab Monotherapy: Is It Only the Tip of the Iceberg?

Authors: Kamiar Mireskandari, Gillian G. W. Adams, Nasrin N. Tehrani

2013 Acta Ophthalmologica

Early vitreoretinal surgery on vascularly active stage 4 retinopathy of prematurity through the preoperative intravitreal bevacizumab injection

Authors: Yu Xu, Qi Zhang, Xiaoli Kang, Ying Zhu, Jiakai Li, Yiye Chen, Peiquan Zhao

2013 American Journal of Ophthalmology

Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.

Authors: Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jonas JB

2013 Acta Ophthalmologica

What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?

Author: Ulrich Spandau

2013 Acta Ophthalmologica

Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?

2012 Taiwan Journal of Ophthalmology

Effects of ranibizumab on very low birth weight infants with stage 3 retinopathy of prematurity: A preliminary report

Authors: Chun-Ju Lin, San-Ni Chen, Chien-Chi Tseng, Yao-Chung Chang, Jiunn-Feng Hwang

2012 Early Human Development

Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors

Author: Helen A. Mintz-Hittner

2012 American Journal of Ophthalmology

Serum Concentrations of Bevacizumab (Avastin) and Vascular Endothelial Growth Factor in Infants With Retinopathy of Prematurity

Authors: Tatsuhiko Sato, Kazuko Wada, Hitomi Arahori, Noriyuki Kuno, Kenji Imoto, Chiharu Iwahashi-Shima, Shunji Kusaka

2012 Journal of Pediatric Ophthalmology and Strabismus

An Evidence-Based Meta-analysis of Vascular Endothelial Growth Factor Inhibition in Pediatric Retinal Diseases: Part 1. Retinopathy of Prematurity

Authors: Mihai Mititelu, Khurram M. Chaudhary, Ronni M. Lieberman

2012 Journal of Pediatric Ophthalmology and Strabismus

Different Refractive Errors in Triplets With Retinopathy of Prematurity Treated With Bevacizumab

Authors: Chien-Chi Tseng, San-Ni Chen, Jiunn-Feng Hwang, Chun-Ju Lin

2012 JAMA Ophthalmology

Significant Treatment Failure With Intravitreous Bevacizumab for Retinopathy of Prematurity

Authors: Ravi Patel, Michael Blair, Michael Shapiro

2012 JAMA Ophthalmology

Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.

Authors: Harder BC, von Baltz S, Schlichtenbrede FC, Jonas JB

2012 Acta Paediatrica

Is Avastin the right choice of treatment for retinopathy of prematurity?

Author: Anna Käll

2012 Eye

Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity

Authors: BJ Lee, JH Kim, H Heo, YS Yu

2012 Journal of Maternal, Fetal & Neonatal Medicine

Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment: A case series

Authors: Carlo Dani, Saverio Frosini, Pina Fortunato, Giovanna Bertini, Simone Prates4, Liliana Pollazz, Roberto Caputo, Agostino La Torre

2012 JAMA Ophthalmology

Reactivation of Retinopathy of Prematurity After Bevacizumab Injection

Authors: Jennifer Hu, Michael P. Blair, Michael J. Shapiro, Steven J. Lichtenstein, John M. Galasso, Rashmi Kapur

2012 Journal of American Academy of Pediatric Ophthalmology and Strabismus

Bevacizumab (Avastin) for retinopathy of prematurity: Wrong dose, wrong drug, or both?

Author: Robert Avery

2011 Ophthalmology

Effects and Complications of Bevacizumab Use in Patients with Retinopathy of Prematurity: A Multicenter Study in Taiwan

Authors: Wei-Chi Wu, Po-Ting Yeh, San-Ni Chen, Chung-May Yang, Chi-Chun Lai, Hsi-Kung Kuo

2011 Middle East African Journal of Ophthalmology

Early Experience with Intravitreal Bevacizumab Combined with Laser Treatment for Retinopathy of Prematurity

Authors: Seemant Raizada, Jamal Al Kandari, Ahmad Al Foudari

2011 Ophthalmology

Retinopathy of Prematurity in the Time of Bevacizumab: Incorporating the BEAT-ROP Results into Clinical Practice

Authors: Darius M. Moshfeghi, California Audina M. Berrocal

2011 Acta Paediatrica

On the use of antiangiogenetic medications for retinopathy of prematurity.

Hard AL, Hellstrom A

2011 New England Medical Journal

Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity

Authors: Helen A. Mintz-Hittner, Kathleen A. Kennedy, Alice Z. Chuang, for the BEAT-ROP Cooperative Group

2010 Graefes Archives for Clinical and Experimental Ophthalmology

Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels

Authors: Joo Yong Lee, Ju Byung Chae, Sung Jae Yang, Young Hee Yoon, June-Gone Kim

2010 Clinical Ophthalmology

Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity

Authors: Raul Velez-Montoya, Carmen Clapp, Jose Carlos Rivera, Gerardo Garcia-Aguirre, Virgilio Morales-Cantón, Jans Fromow-Guerra, Jose Luis Guerrero-Naranjo, Hugo Quiroz-Mercado

2010 Journal of American Academy of Pediatric Ophthalmology and Strabismus

Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity

Authors: Janice C. Law, Franco M. Recchia, David G. Morrison, Sean P. Donahue, Robert L. Estes

2010 JAAPOS

Avastin as monotherapy for retinopathy of prematurity

Author: Helen A. Mintz-Hittner

2009  Current Opinion in Pediatrics

Antivascular endothelial growth factor for retinopathy of prematurity

Authors: Helen A. Mintz-Hittner, Leah M. Best

2009 Developmental Ophthalmology

Anti-Angiogenic Therapy in the Management of Retinopathy of Prematurity

Author: Kimberly A. Drenser

2009 American Journal of Ophthalmology

A Systematic Analysis of the Off-Label Use of Bevacizumab for Severe Retinopathy of Prematurity

Authors: Jonathan A. Micieli, Michael Surkont, Andrew F. Smith

2009 Eye (London)

Paradoxical vascular–fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity

Authors: Luz Consuelo Zepeda-Romero, JA Liera-Garcia, JA Gutiérrez-Padilla, CI Valtierra-Santiago, LJ Cardenas-Lamas

2009 Retina

Concentration of VEGF in aqueous humor of eyes with advanced ROP before and after intravitreal injection of bevacizumab

Authors: N Nonobe, S Kachi, M Kondo, Y Takai, K Takemoto, A Nakayama, M Hayakawa, H Terasaki

2008 Retina

Antiangiogenic Therapy with Intravitreal Bevacizumab for Retinopathy of Prematurity

Authors: Hugo Quiroz-Mercado, Maria Ana Martinez-Castellanos, Myriam L Hernandez-Rojas, Nelida Salazar-Teran, Robinson Vernon Paul Chan

2008 Retina

Intravitreal Injection of Bevacizumab (Avastin) for Treatment of Stage 3 Retinopathy of Prematurity in Zone I or Posterior Zone II

Authors: Helen A. Mintz-Hittner, Ronald Kuffel Jr.

2008 Retina

Off-label use of Intravitreal Bevacizumab (Avastin) for Salvage Treatment in Progressive Threshold Retinopathy of Prematurity

Authors: Geeta A. Lalwani, Audina M. Berrocal, Timothy G. Murray, Maria Buch, Scott Cardone, Ditte Hess, Rose A. Johnson, Carmen A. Puliafito

2008 Graefes Archives of Clinical and Experimental Ophthalmology

Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity

Authors: Shigeru Honda, Hiroaki Hirabayashi, Yasutomo Tsukahara, Akira Negi

2008 Acta Ophthalmologica

Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity

Authors: Roberto dell’Omo, Avinash Kulkarni, Wendy A. Franks

2008 Archives of Ophthalmology

Intravitreous Bevacizumab as Anti–Vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity: A Morphologic Study

Authors: Lingkun Kong, Helen A. Mintz-Hittner, Rebecca L. Penland, Francis L. Kretzer, Patricia Chévez-Barrios

2007 Indian Journal of Ophthalmology

Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity

Parag K Shah, V Narendran, Khaled A Tawansy,  A Raghuram, Kalpana Narendran

2007 Ophthalmic Surgery Lasers Imaging

Intravitreal Bevacizumab in Aggressive Posterior Retinopathy of Prematurity

António Travassos, Susana Teixeira, Pinto Ferreira, Isaura Regadas, Ana Sofia Travassos, Florindo Esteves Esperancinha, Isabel Prieto, Graça Pires, Robert van Velze, A. Valido, Maria do Céu Machado

2007 Graefes Archives for Clinical and Experimental Ophthalmology

Combination of laser photocoagulation and intravitreal bevacizumab (Avastin®) for aggressive zone I retinopathy of prematurity

Eun Jee Chung, Ji Hyun Kim, Hyun Seok Ahn, Hyoung Jun Koh

2006 Retina

Testing Intravitreal Toxicity of Bevacizumab (Avastin) 

Roberta P. A. Manzano, Gholan A. Peyman, Palwasha Khan, Muhamet Kivilcim

THE CUTTING EDGE OF RETINOPATHY OF PREMATURITY CARE:

Expanding the Boundaries of Diagnosis and Treatment.

Authors: Yonekawa Y, Thomas BJ, Thanos A, Todorich B, Drenser KA, Trese MT, Capone A Jr.

PURPOSE: To discuss the latest advances and controversies in the diagnosis and care of infants with ROP.

METHODS: Literature review.

RESULTS: ROP remains a major global issue. Industrialized nations now treat profoundly premature infants with posterior and aggressive disease, and middle-income nations are experiencing ROP epidemics. Remote digital imaging may address the decreasing ratio of ROP providers to premature infants, in addition to improving patient care. Widefield angiography, optical coherence tomography, and the Wnt signaling pathway have provided new insights into ROP pathogenesis. Anti-vascular endothelial growth factor treatment is increasing in popularity, but the dearth of information to guide dosing, unpredictable reactivation, persistent vascular abnormalities, the "crunch" phenomenon, and the presently unknown effects of systemic vascular endothelial growth factor suppression remain issues to continue investigating. Neurodevelopmental delay has been raised as a potential consequence, but the evidence currently is weak. Vitrectomy is the treatment of choice for Stages 4 and 5. Illumination techniques, ab interno incisions, plasmin-assisted vitrectomy, staged surgery in the interest of corneal clearing for advanced Stage 5, and immediate sequential bilateral vitreoretinal surgery, are useful techniques.

CONCLUSION: We are making progress in ROP management. Our goal as clinicians is to continue expanding the boundaries of our abilities to keep this blinding disease in check globally.

Publicado en el Case Reports in Ophthalmological Medicine Volume 2015,

Huseyin Gursoy,1 Nazmiye Erol,1 Mustafa Deger Bilgec,1 Hikmet Basmak,1Ozden Kutlay,2 and Huseyin Aslan2

1Department of Ophthalmology, Eskis¸ehir Osmangazi University Medical Faculty, 26180 Eskis¸ehir, Turkey
2Department of Medical Genetics, Eskis¸ehir Osmangazi University Medical Faculty, 26180 Eskis¸ehir, Turkey

ABSTRACT

To report a case of bilateral Coats’ disease combinedwith retinopathy of prematurity (ROP). Case. Retinal vascularization was complete in the right eye, whereas zone III, stage 3 ROP and preplus disease were observed in the left eye at 43 weeks of postmenstrual age (PMA) in a 31-week premature, 1200-g neonate. Intraretinal exudates developed and retinal hemorrhages increased in the left eye at 51 weeks of PMA. Diode laser photocoagulation (LP) was applied to the left eye. Exudates involved the macula, and telangiectatic changes developed one month following LP. Additional LP was applied to the left eye combined with intravitreal bevacizumab (IVB) injection at 55 weeks of PMA. Disease regressed onemonth after the additional therapy. At the 14-month examination of the baby, telangiectatic changes and intraretinal exudates were observed in the right eye.Diode LP was applied to the right eye combinedwith IVBinjection. Exudates did not resolve completely, and cryotherapy was applied onemonth following LP. Retinal findings regressed three months following the cryotherapy. Conclusion. This is the first report of presumed bilateral Coats’ disease combined with ROP. If Coats’ disease could be diagnosed at early stages, it would be a disease associated with better prognosis.

Grupo ROP México

Andrea Zin

Marco A. de la Fuente Torres

Clare Gilbert

Graham E. Quinn

Ministerio de Salud

Presidencia de la Nación

Republica Argentina

Guía Clínica Diagnóstica

Viña del Mar

Chile

Christoffel Blindenmission

International Centre for Eye Health

London School Hygiene and Tropical Medicine

Archivos para Download:

1) English version

2) Spanish Version

Secretaria de Salud

Centro Nacional de Equidad de Género y Salud Reproductiva

Ciudad de México DF

México

Clare Gilbert & Allen Foster

The major causes of blindness in children vary widely from region to region, being largely determined by socioeconomic development, and the availability of primary health care and eye care services. In high-income countries, lesions of the optic nerve and higher visual pathways predominate as the cause of blindness, while corneal scarring from measles, vitamin A deficiency, the use of harmful traditional eye remedies, and ophthalmia neonatorum are the major causes in low-income countries.

Retinopathy of prematurity is an important cause in middle-income countries. Other significant causes in all countries are cataract, congenital abnormalities, and hereditary retinal dystrophies. It is estimated that, in almost half of the children who are blind today, the underlying cause could have been prevented, or the eye condition treated to preserve vision or restore sight.

The control of blindness in children is a priority within the World Health Organization’s VISION 2020 programme. Strategies need to be region specific, based on activities to prevent blindness in the community - through measles immunization, health education, and control of vitamin A deficiency and the provision of tertiary-level eye care facilities for conditions that require specialist management.